BIIB News and Press, Biogen Inc. From 05/16/24

Development of BIIB105, an investigational antisense oligonucleotide for amyotrophic lateral sclerosis (ALS), will be discontinued based on data from the Phase 1/2 ALSpire study Biogen and Ionis continue their long-standing commitment to developing therapies for ALS given the devastating impa...

2024-05-15 12:52:06 ET More on Eisai Eisai: All About Lenvima And Leqembi Biogen partner Eisai begins FDA submissions for injectable Alzheimer’s therapy Biogen’s Alzheimer's drug to cost $3.5B for Medicare in 2025: report Historical earnings dat...

2024-05-15 07:44:07 ET More on Biogen, Eisai Co., Ltd., etc. Biogen: Reasons To Be Cheerful After Upbeat Q1 Earnings Biogen: Don't Overthink This One Biogen's Revenue Dip Meets Cost Cuts In Q1 (Rating Upgrade) Biogen says uptake for Alzheimer’s therapy...

Eisai Initiates Rolling Biologics License Application to US FDA for LEQEMBI® (lecanemab-irmb) for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease Under the Fast Track Status PR Newswire TOKYO and CAMBRIDGE, Mass. , May 14, 2024...

2024-05-11 08:00:00 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips The extraordinary performance of Nvidia (NASDAQ: NVDA ) in 2023 coincided with a seismic generative-AI rally that carried the entirety of the S&P 500 higher in a year th...

2024-05-09 06:30:00 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Here’s a question for you: What determines the value of a drug ? Is it the number of lives it saves or how much it costs to make? Is it the deadliness of the disease it prevents or t...

2024-05-07 20:26:14 ET Summary Our 3-step process focuses on wide-moat stocks (as per Morningstar’s rating). We are only interested in those targets that are attractively valued in historical comparison. We share the heat map of the most investable candidates that may b...

2024-05-07 09:38:29 ET More on Eli Lilly Eli Lilly: Great Time To Divest Before It Potentially Crashes Eli Lilly Remains Expensive Here - Minimal Margin Of Safety Eli Lilly: Don't Overpay For Miracle Drugs Pharma R&D productivity seen improving for the fi...

Efforts focused on four areas: access and health equity, workforce and DE&I, community impact and the environment CAMBRIDGE, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced publication of its 2023 Corporate Responsibility Report detailing pro...

2024-05-01 11:44:29 ET More on AbCellera Biologics AbCellera: Victim Of Its Own Success AbCellera Biologics Inc. (ABCL) Q4 2023 Earnings Call Transcript AbCellera Biologics: Continuing To Expand Partnerships Peter Thiel resigns from AbCellera board for person...